Alkermes
ALKS • NASDAQ
Alkermes is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Richard F. Pops, with a market cap of $5.5B.
CEORichard F. Pops
Market Cap$5.5B
Biotechnology
Healthcare
Employees2.1K
Websitealkermes.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Alkermes
Date
Thursday, April 30, 2026 (in 3 months)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.26
Revenue Estimate
$356.1M
Earnings History
Past 11 earnings reports for Alkermes
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Oct 28, 2025 | Q3 2025 | $0.49Est: $0.37 | +32.4% | $394.2MEst: $356.0M | +10.7% | — |
| Jul 29, 2025 | Q2 2025 | $0.52Est: $0.34 | +52.9% | $390.7MEst: $340.3M | +14.8% |  10-Q |
| May 1, 2025 | Q1 2025 | $0.13Est: $0.24 | -45.8% | $306.5MEst: $304.1M | +0.8% | 10-Q |
| Feb 12, 2025 | Q4 2024 | $1.04Est: $0.76 | +36.8% | $430.0MEst: $379.4M | +13.3% | 10-K |
| Oct 24, 2024 | Q3 2024 | $0.72Est: $0.74 | -2.7% | $378.1MEst: $380.6M | -0.7% | 10-Q |
| Jul 24, 2024 | Q2 2024 | $0.72Est: $0.70 | +2.9% | $399.1MEst: $393.4M | +1.5% | 10-Q |
| May 1, 2024 | Q1 2024 | $0.44Est: $0.58 | -24.1% | $350.4MEst: $360.3M | -2.7% | 10-Q |
| Feb 15, 2024 | Q4 2023 | $0.48Est: $0.51 | -5.9% | $377.5MEst: $362.0M | +4.3% | 10-K |
| Oct 25, 2023 | Q3 2023 | $0.64Est: $0.43 | +48.8% | $380.9MEst: $362.2M | +5.2% | 10-Q |
| Jul 26, 2023 | Q2 2023 | $0.55Est: $0.56 | -1.8% | $617.4MEst: $585.0M | +5.5% | 10-Q |
| Apr 26, 2023 | Q1 2023 | $0.01Est: -$0.02 | +150.0% | $287.6MEst: $282.2M | +1.9% | 10-Q |